Form 4: Inhibrx Biosciences President David Matly Acquires 50,000 Stock Options
SEC Filing
David Matly, President of Inhibrx Biosciences, acquired 50,000 stock options on April 1, 2025, according to a Form 4 filing.
Summary
- David Matly, President of Inhibrx Biosciences, filed a Form 4 with the SEC.
- The filing reports the acquisition of 50,000 stock options on April 1, 2025.
- The exercise price of the stock options is $14.05.
- The options expire on April 1, 2035.
- 25% of the options will become exercisable on April 1, 2026, with the remainder vesting monthly over the following 36 months, contingent on continuous service.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard executive compensation practice.
Future Outlook
The stock options vest over time, incentivizing the Reporting Person's continued service to the Issuer.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The granting of stock options aligns management's interests with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of earliest transaction: Acquisition of 50,000 stock options. |
| 04/01/2025 | Stock options granted. |
| 04/01/2026 | 25% of stock options become exercisable. |
| 04/02/2025 | Date of Form 4 filing. |
| 04/01/2035 | Expiration date of the stock options. |
Keywords
Form 4, stock options, Inhibrx Biosciences, David Matly, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.